A comparative study of 500 mg BID and 250 mg BID of prophylactic oral ganciclovir in post-kidney transplant 'CMV at risk' recipients

Transplantation Proceedings

Volumn 31, Issue 1-2, 1999, Pages 1125-1126

  Yang, H C ^a   Holman, M J ^a   Langhoff, E ^b   Dellock, C A ^a   Gupta, M ^a   Ulsh, P J ^a   Ahsan, N ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MICROEMULSION; MORBIDITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC RESEARCH DESIGN; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 0032987462     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(98)01930-7     Document Type: Conference Paper

References (7)

1. Weir M.R., Irwin B.C., Maters A.W., et al. Transplantation. 43:1987;187.
2. Bia M.J., Andiman W., Gaudio J., et al. Transplantation. 40:1985;610.
3. Ahsan N., Holman M.J., Yang H.C. Clin Transplant. 11:1997;633.
4. Ahsan N., Holman M.J., Soderbye L., et al. Transplant Proc. 30:1998;1383.
5. Crumpacker C.S. N Engl J Med. 335:1996;721.
6. Anderson R.D., Griffy K.G., Jung D., et al. Clin Ther. 17:1995;425.
7. Physicians Desk Reference. Montvale, NJ: Medical Economics Publishing; 1998, p 2452.